Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.

Autor: Rashitov M; Partners In Health Kazakhstan, Almaty, Kazakhstan., Franke MF; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Trevisi L; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA., Bekbolatova G; Atyrau Regional Center of Phthisiopulmonology, Atreyu, Kazakhstan., Shalimova J; Karaganda Regional Center of Phthisiopulmonology, Karaganda, Kazakhstan., Eshmetov G; Turkistan Regional Center of Phthisiopulmonology, Turkistan, Kazakhstan., Bektasov S; National Scientific Center of Phthisiopulmonology, Almaty, Kazakhstan., LaHood A; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Arlyapova N; Partners In Health, Boston, Massachusetts, USA., Osso E; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA., Yedilbayev A; World Health Organization, Regional Office for Europe, Copenhagen, Denmark., Korotych O; World Health Organization, Regional Office for Europe, Copenhagen, Denmark., Ciobanu A; World Health Organization, Regional Office for Europe, Copenhagen, Denmark., Skrahina A; The Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus., Mitnick CD; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.; Partners In Health, Boston, Massachusetts, USA.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA., Seung KJ; Partners In Health, Boston, Massachusetts, USA.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA., Algozhin Y; Partners In Health Kazakhstan, Almaty, Kazakhstan., Rich ML; Partners In Health, Boston, Massachusetts, USA.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Oct 15; Vol. 79 (4), pp. 1046-1053.

Reply to Cohen et al. and to Lee.

Autor: Trevisi L; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts., Brooks MB; Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts., Murray MB; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts; and.; Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Huang CC; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts; and.; Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Publikováno v: American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2024 Sep 15; Vol. 210 (6), pp. 850-852.

Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.

Autor: Trevisi L; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts., Brooks MB; Department of Global Health, Boston University School of Public Health, Boston, Massachusetts., Becerra MC; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts., Calderón RI; Socios en Salud, Lima, Peru., Contreras CC; Socios en Salud, Lima, Peru.; Harvard Global Health Institute, Cambridge, Massachusetts., Galea JT; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.; College of Behavioral and Community Sciences, School of Social Work, University of South Florida, Tampa, Florida; and., Jimenez J; Socios en Salud, Lima, Peru., Lecca L; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.; Socios en Salud, Lima, Peru., Yataco RM; Socios en Salud, Lima, Peru., Tovar X; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts., Zhang Z; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts., Murray MB; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts.; Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Huang CC; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts.; Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

Publikováno v: American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2024 Jul 15; Vol. 210 (2), pp. 222-233.

Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis.

Autor: Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, Hewison C, Bastard M, Khan P, Seung KJ, Rich ML, Law S, Kikvidze M, Kirakosyan O, Miankou A, Thit P, Mamsa S, Janmohamed A, Melikyan N, Ahmed S, Vargas D, Binegdie AB, Temirova K, Oyewusi L, Philippe K, Vilbrun SC, Khan U, Huerga H, Franke MF

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2024 Jan 19. Date of Electronic Publication: 2024 Jan 19.

MiR-206 inhibits estrogen signaling and ovarian cancer cell migration without affecting GPER.

Autor: Boscaro C; Department of Medicine, University of Padova, Italy., Ramaschi GE; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy., Trevisi L; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy., Cignarella A; Department of Medicine, University of Padova, Italy., Bolego C; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy. Electronic address: chiara.bolego@unipd.it.

Publikováno v: Life sciences [Life Sci] 2023 Nov 15; Vol. 333, pp. 122135. Date of Electronic Publication: 2023 Sep 30.